In this Phase 3b, open-label, randomized controlled clinical trial, 751 adult participants with obesity but without type 2 diabetes (BMI 30 or BMI 27 with at least one obesity-related comorbidity, such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous injections of the maximum tolerated dose of Tirzepatide (10 mg or 15 mg) or Semaglutide (1.7 mg or 2.4 mg) for 72 weeks
Whether seeking a diabetes medicine for weight loss or exploring innovative treatment options, understanding these medications could be a game-changer
Food and Drug Administration (FDA) approved Ozempic with a new indication: to reduce the risk of kidney disease worsening and cardiovascular death in adults with type 2 diabetes and chronic kidney disease a major clinical milestone demonstrating broader therapeutic value beyond glycemic control
The personalized approach made all the difference. Emily R
We recommend 8 weeks on, followed by 4 weeks off before starting another cycle if needed
By the weekend, levels are still therapeutic but slightly lower, which some researchers actually prefer since it allows for more flexible social eating